Neoadjuvant therapy with PD-L1 inhibitor

DRUG2 trials

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Colorectal CancerEsophageal CancerMicrosatellite Instability-high (MSI-H)Mismatch Repair-deficient (dMMR)Neoadjuvant Therapy

Phase 2

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Third Affiliated Hospital, Sun Yat-Sen UniversityColorectal Cancer, Microsatellite Instability-high (MSI-H), Mismatch Repair-deficient (dMMR) +1

Start: 2022-05-05End: 2024-12-31Target: 26Updated: 2022-05-12

Unknown Phase

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Not yet recruitingNCT06889402

Cancer Institute and Hospital, Chinese Academy of Medical SciencesEsophageal Cancer

Start: 2025-04-01End: 2025-04-30Target: 600Updated: 2025-03-21